Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK2FSY)

• Drug Name: Pyrrolo-pyridinone derivative 5 Drug Info
• Synonyms: PMID25539043-Compound-WO2013161312Example15
• Cross-matching ID: TTD Drug ID: DMK2FSY

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.7 (SCN9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEN-402	DMR69CG	Osteoarthritis	FA00-FA05	Phase 2	[2]
PF-05089771	DMD74BJ	Chronic pain	MG30	Phase 2	[3]
BIIB074	DMLV1ET	Bipolar disorder	6A60	Phase 2	[4]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[4]
BIIB095	DMUC6EP	Pain	MG30-MG3Z	Phase 1	[4]
GDC0310	DMUNFEP	Chronic pain	MG30	Phase 1	[5]
DSP-3905	DMYHU24	Neuropathic pain	8E43.0	Phase 1	[4]
PF-05241328	DM2NTBL	Pain	MG30-MG3Z	Phase 1	[6]
DWJ-208	DMQKDJZ	Cancer related pain	MG30	Phase 1	[4]
RG7893	DM1R4MQ	Pain	MG30-MG3Z	Phase 1	[7]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.3 (SCN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lidoflazine	DMV23GL	Angina pectoris	BA40	Approved	[8]
Aryl carboxamide derivative 1	DMTZRCW	N. A.	N. A.	Patented	[1]
Aryl carboxamide derivative 2	DM146TA	N. A.	N. A.	Patented	[1]
Pyrimidine derivative 1	DMN9VQM	N. A.	N. A.	Patented	[1]
Pyrrolo-pyridinone derivative 6	DMXGNP8	N. A.	N. A.	Patented	[1]
Sipatrigine	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[9]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[10]
PD-85639	DMNUKB4	N. A.	N. A.	Terminated	[8]
Batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[11]
Veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.3 (SCN3A)	TTAXZ0K	SCN3A_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.7 (SCN9A)	TT4G2JS	SCN9A_HUMAN	Inhibitor	[1]

References

• [1] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [2] Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
• [3] Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
• [4] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
• [8] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [9] Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
• [10] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).